文献速递肝病

熊去氧胆酸治疗原发性胆汁性胆管炎患者风险评分系统的验证

Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

本研究基于欧洲、美国和加拿大25个中心的1746例UDCA治疗的PBC患者数据,评估GLOBE和UK-PBC风险评分系统及UDCA应答标准对肝硬化相关并发症的预测性能。中位随访7年,171例达到临床终点,GLOBE和UK-PBC评分预测优于UDCA应答标准,两者预后性能相似且优异。

要点

  • GLOBE和UK-PBC风险评分对肝硬化相关并发症的预测优于UDCA应答标准。
  • GLOBE评分每增加1个标准差,风险比HR为5.05(95%CI 4.43-5.74,P<0.001)。
  • UK-PBC评分每增加1个标准差,风险比HR为3.39(95%CI 3.10-3.72,P<0.001)。

核心结论

  • 在国际多中心PBC队列中,GLOBE和UK-PBC风险评分系统能良好预测未来肝硬化相关并发症。

研究设计与样本

  • 研究纳入欧洲、美国、加拿大25个中心的1746例UDCA治疗的PBC患者数据。
  • 评估GLOBE和UK-PBC风险评分系统及Barcelona、Paris I、Paris II、Rotterdam、Toronto等UDCA应答标准的预后性能。
  • 临床终点定义为肝硬化相关并发症(腹水、静脉曲张出血和/或肝性脑病)。

主要发现

  • 中位随访7年(范围1-16年),171例患者达到临床终点。
  • 5年、10年和15年无不良结局生存率分别为95%、85%和77%。
  • GLOBE和UK-PBC评分预测肝硬化相关并发症优于UDCA应答标准。
  • GLOBE评分每增加1个标准差,HR为5.05(95%CI 4.43-5.74,P<0.001)。
  • UK-PBC评分每增加1个标准差,HR为3.39(95%CI 3.10-3.72,P<0.001)。

临床怎么用

  • 原文未提及临床实践应用的具体建议。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Risk stratification based on biochemical variables is a useful tool for monitoring ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC). Several UDCA response criteria and scoring systems have been proposed for risk prediction in PBC, but these have not been validated in large external cohorts. METHODS: We performed a study on data of 1746 UDCA-treated patients with PBC from 25 centers in Europe, United States, and Canada. The prognostic performance of the risk scoring systems (GLOBE and UK-PBC) and the UDCA response criteria (Barcelona, Paris I, Paris II, Rotterdam, and Toronto) were evaluated. We regarded cirrhosis-related complications (ascites, variceal bleeding, and/or hepatic encephalopathy) as clinical end points. RESULTS: A total of 171 patients reached a clinical end point during a median 7 years (range 1-16 years) of follow-up. The 5-, 10- and 15-year adverse outcome-free survivals were 95%, 85%, and 77%. The GLOBE and UK-PBC scores predicted cirrhosis-related complications better than the UDCA response criteria. The hazard ratio (HR) for a 1 standard deviation increase was HR 5.05 (95% confidence interval (CI): 4.43-5.74, P < 0.001) for the GLOBE score and HR 3.39 (95% CI: 3.10-3.72, P < 0.001) for the UK-PBC score. Overall, the GLOBE and UK-PBC risk scores showed similar and excellent prognostic performance (C-statistic, 0.93; 95% CI: 0.91%-95% vs 0.94; 95% CI: 0.91%-0.96%). DISCUSSION: In our international, multicenter PBC cohort, the GLOBE and UK-PBC risk scoring systems were good predictors of future cirrhosis-related complications.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Efe C, Taşçilar K, Henriksson I, et al. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. Am J Gastroenterol. 2019. PMID: 31241547. doi:10.14309/ajg.0000000000000290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。